Showing results (381-390 of 397) with videos related to
Sort By:
Pageof 40
Nature Immunology|February 21, 2012
The earliest thymic T cell progenitors sustain B cell and myeloid lineage potentialSidinh Luc, Tiago C Luis, Hanane Boukarabila, et al.Molecular Neurodegeneration|November 4, 2025
M102 activates both NRF2 and HSF1 transcription factor pathways and is neuroprotective in cell and animal models of amyotrophic lateral sclerosisAmy F Keerie, Raquel Rua Martins, Chloe F Allen, et al.Blood|December 9, 2022
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapyAnnatina S Schnegg-Kaufmann, Julie A I Thoms, Golam Sarower Bhuyan, et al.Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.Nature Genetics|September 4, 2023
Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolutionAlba Rodriguez-Meira, Ruggiero Norfo, Sean Wen, et al.Science (New York, N.Y.)|August 14, 2025
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNALauren Murphy, Jeanne Inchauspé, Giampiero Valenzano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialClaire N Harrison, Jyoti Nangalia, Rebecca Boucher, et al.Biorxiv : the Preprint Server for Biology|December 18, 2023
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1AC K Brierley, B H Yip, G Orlando, et al.Nature Communications|November 24, 2023
Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysisZijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, et al.Science Translational Medicine|October 9, 2024
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axisRong Li, Michela Colombo, Guanlin Wang, et al.Pageof 40